OVERVIEW
Drug Overview
Product Profiles
Off-label: Rituxan: Systemic lupus erythematosus (SLE)
Rituxan: Chronic lymphocytic leukemia (CLL)
Rituxan: NHL: Follicular lymphoma (FL)
Rituxan: NHL: Diffuse large B-cell lymphoma (DLBCL)
Rituxan: Rheumatoid arthritis (RA)
Rituxan: NHL: Mantle cell lymphoma (MCL)
LIST OF FIGURES
Figure 1: Rituxan for SLE – SWOT analysis
Figure 2: The authors drug assessment summary of Rituxan for SLE
Figure 3: The authors drug assessment summary of Rituxan for SLE
Figure 4: Rituxan sales for SLE across the US and five major EU markets, by region, 2016–25
Figure 5: The authors drug assessment summary of Rituxan for CLL
Figure 6: The authors drug assessment summary of Rituxan for CLL
Figure 7: Rituxan sales for CLL across the US, Japan, and five major EU markets, by country, 2017–26
Figure 8: Rituxan for follicular lymphoma – SWOT analysis
Figure 9: The authors drug assessment summary of Rituxan for follicular lymphoma
Figure 10: The authors drug assessment summary of Rituxan for follicular lymphoma
Figure 11: Rituxan sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 12: Rituxan for diffuse large B-cell lymphoma – SWOT analysis
Figure 13: The authors drug assessment summary for Rituxan in diffuse large B-cell lymphoma
Figure 14: The authors drug assessment summary for Rituxan in diffuse large B-cell lymphoma
Figure 15: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 16: Rituxan for rheumatoid arthritis – SWOT analysis
Figure 17: The authors drug assessment summary of Rituxan in rheumatoid arthritis
Figure 18: The authors drug assessment summary of Rituxan in rheumatoid arthritis
Figure 19: Rituxan for mantle cell lymphoma – SWOT analysis
Figure 20: The authors drug assessment summary of Rituxan in mantle cell lymphoma
Figure 21: The authors drug assessment summary of Rituxan in mantle cell lymphoma
LIST OF TABLES
Table 1: Rituxan drug profile
Table 2: Rituxan pivotal trial data in SLE
Table 3: Rituxan sales for SLE across the US and five major EU markets, by region ($m), 2016–25
Table 4: Rituxan drug profile
Table 5: Approval history of Rituxan for CLL in the US, Japan, and five major EU markets
Table 6: Trials of Rituxan for CLL
Table 7: Rituxan for CLL – SWOT analysis
Table 8: Rituxan drug profile
Table 9: Rituxan pivotal trial data in follicular lymphoma
Table 10: Rituxan other clinical trial data in follicular lymphoma
Table 11: Rituxan sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 12: Rituxan drug profile
Table 13: Rituxan pivotal trial data in diffuse large B-cell lymphoma
Table 14: Rituxan Phase III data in diffuse large B-cell lymphoma
Table 15: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 16: Rituxan drug profile
Table 17: Rituxan pivotal trial data in rheumatoid arthritis
Table 18: Rituxan late-phase trial data in rheumatoid arthritis
Table 19: Rituxan drug profile
Table 20: Rituxan pivotal trial data in B-cell non-Hodgkin’s lymphoma
Table 21: Rituxan clinical studies in mantle cell lymphoma
